ScoreWhy is Strides Pharma Science Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 7.27%
- Poor long term growth as Net Sales has grown by an annual rate of 9.32% and Operating profit at 15.52% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.10 times
2
With a growth in Net Profit of 133.64%, the company declared Very Positive results in Dec 25
- The company has declared positive results for the last 10 consecutive quarters
- OPERATING PROFIT TO INTEREST(Q) Highest at 5.44 times
- PAT(Q) At Rs 204.91 cr has Grown at 128.0%
- ROCE(HY) Highest at 16.05%
3
With ROCE of 15.6, it has a Attractive valuation with a 2.5 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 64.43%, its profits have fallen by -8.5%
4
30.6% of Promoter Shares are Pledged
- In falling markets, high promoter pledged shares puts additional downward pressure on the stock prices
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Strides Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Strides Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Strides Pharma
64.43%
1.58
40.82%
Sensex
2.25%
0.17
13.54%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.32%
EBIT Growth (5y)
15.52%
EBIT to Interest (avg)
1.36
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.59
Sales to Capital Employed (avg)
0.78
Tax Ratio
15.33%
Dividend Payout Ratio
1.03%
Pledged Shares
30.60%
Institutional Holding
42.55%
ROCE (avg)
6.82%
ROE (avg)
7.67%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
17
Industry P/E
32
Price to Book Value
3.36
EV to EBIT
15.41
EV to EBITDA
12.03
EV to Capital Employed
2.49
EV to Sales
2.30
PEG Ratio
NA
Dividend Yield
0.40%
ROCE (Latest)
15.60%
ROE (Latest)
15.82%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
OPERATING PROFIT TO INTEREST(Q)
Highest at 5.44 times
PAT(Q)
At Rs 204.91 cr has Grown at 128.0%
ROCE(HY)
Highest at 16.05%
DEBT-EQUITY RATIO(HY)
Lowest at 0.67 times
PBDIT(Q)
Highest at Rs 235.95 cr.
PBT LESS OI(Q)
Highest at Rs 141.92 cr.
DEBTORS TURNOVER RATIO(HY)
Highest at 4.15 times
OPERATING PROFIT TO NET SALES(Q)
Highest at 19.75%
EPS(Q)
Highest at Rs 21.93
-4What is not working for the Company
PAT(9M)
At Rs 446.82 cr has Grown at -22.46%
NON-OPERATING INCOME(Q)
is 42.95 % of Profit Before Tax (PBT
Loading Valuation Snapshot...
Here's what is working for Strides Pharma
Operating Profit to Interest - Quarterly
Highest at 5.44 times and Grown
each quarter in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Profit After Tax (PAT) - Quarterly
At Rs 204.91 cr has Grown at 128.0%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 235.95 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 141.92 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 204.91 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Debt-Equity Ratio - Half Yearly
Lowest at 0.67 times and Fallen
each half year in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Operating Profit Margin - Quarterly
Highest at 19.75%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 141.92 cr has Grown at 28.25%
Year on Year (YoY)MOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 21.93
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Debtors Turnover Ratio- Half Yearly
Highest at 4.15 times
in the last five half yearly periodsMOJO Watch
Company has been able to settle its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Strides Pharma
Non Operating Income - Quarterly
is 42.95 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model
Non Operating Income to PBT
Non Operating Income - Quarterly
Highest at Rs 106.86 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
